palonosetron + dexamethasone + fosaprepitant

This triple-combination antiemetic therapy consists of fosaprepitant (150 mg), palonosetron (0.075 mg), and dexamethasone (5 mg). It is being investigated by the Sixth Affiliated Hospital of Sun Yat-sen University for the prevention of postoperative nausea and vomiting (PONV) in high-risk patients, particularly those undergoing laparoscopic gastrointestinal surgery. The regimen utilizes three distinct mechanisms of action: fosaprepitant acts as a neurokinin-1 (NK-1) receptor antagonist, palonosetron is a second-generation 5-HT3 receptor antagonist, and dexamethasone is a corticosteroid that functions as a glucocorticoid receptor agonist. A Phase 3 randomized, double-blind trial demonstrated that this triple therapy significantly reduced the incidence of PONV during the first 24 postoperative hours compared to dual therapy with palonosetron and dexamethasone alone.

Other names

Fosaprepitant Triple Therapy